NCT07019922View on ClinicalTrials.gov

A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety

PHASE3RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 13, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2028

Conditions
Epileptic EncephalopathySCN2A Encephalopathy
Interventions
DRUG

1mg elsunersen

24 weeks every 4 weeks intrathecally

PROCEDURE

sham procedure

24 weeks of sham-procedure every 4 weeks

DRUG

0.5mg elsunersen

24 weeks every 4 weeks intrathecally

Trial Locations (2)

60612

RECRUITING

Praxis Research Site, Chicago

92123

RECRUITING

Praxis Research Site, San Diego

Sponsors
All Listed Sponsors
lead

Praxis Precision Medicines

INDUSTRY

NCT07019922 - A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety | Biotech Hunter | Biotech Hunter